Search Results - P. Valent

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    Aggressive systemic mastocytosis with sarcoma-like growth in the skeleton, leukemic progression, and partial loss of mast cell differentiation antigens by M.T. Krauth, M. Födinger, L. Rebuzzi, R. Greul, A. Chott, P. Valent

    Published in Haematologica (2007-12-01)
    Get full text
    Article


  2. 2

    P993: SETD2 IS A BONA FIDE TUMOR SUPPRESSOR IN SYSTEMIC MASTOCYTOSIS by M. Mancini, C. Monaldi, S. De Santis, C. Papayannidis, M. Rondoni, C. Sartor, S. Bruno, A. Curti, R. Zanotti, M. Bonifacio, L. Scaffidi, L. Pagano, M. Criscuolo, F. Ciceri, C. Elena, P. Tosi, P. Valent, M. Cavo, S. Soverini

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  3. 3

    C018 | OVERALL SURVIVAL AND DURATION OF TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR BEST AVAILABLE THERAPY IN A REAL-WORLD... by A. M. Vannucchi, A. Reiter, J. Gotlib, I. Álvarez-Twose, D. H. Radia, J. Luebke, P. J. Bobbili, A. Wang, S. Dimitrijević, E. Sullivan, J. Schwaab, I. A. Galinsky, C. Perkins, W. R. Sperr, P. Sriskandarajah, M. Mohan, T. Badu, M. S. Duh, P. Valent

    Published in Haematologica (2025-09-01)
    Get full text
    Article


  4. 4

    Hyper-resolution flood hazard mapping at the national scale by G. Blöschl, A. Buttinger-Kreuzhuber, A. Buttinger-Kreuzhuber, D. Cornel, J. Eisl, M. Hofer, M. Hollaus, Z. Horváth, Z. Horváth, J. Komma, A. Konev, J. Parajka, N. Pfeifer, A. Reithofer, J. Salinas, J. Salinas, P. Valent, R. Výleta, J. Waser, M. H. Wimmer, H. Stiefelmeyer

    Published in Natural Hazards and Earth System Sciences (2024-06-01)
    Get full text
    Article


  5. 5

    P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE by A. Reiter, J. Gotlib, I. Álvarez-Twose, D. H. Radia, J. Luebke, P. J. Bobbili, A. Wang, C. Norregaard, S. Dimitrijević, E. Sullivan, M. Louie-Gao, J. Schwaab, I. A. Galinsky, C. Perkins, W. R. Sperr, P. Sriskandarajah, A. Chin, S. R. Sendhil, M. S. Duh, P. Valent, D. J. DeAngelo

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  6. 6

    P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY by A. Reiter, J. Gotlib, I. Álvarez-Twose, D. H. Radia, J. Luebke, P. J. Bobbili, A. Wang, C. Norregaard, S. Dimitrijević, E. Sullivan, M. Louie-Gao, J. Schwaab, I. A. Galinsky, C. Perkins, W. R. Sperr, P. Sriskandarajah, A. Chin, S. R. Sendhil, M. S. Duh, P. Valent, D. J. DeAngelo

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  7. 7

    P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY by A. Reiter, J. Gotlib, I. Álvarez-Twose, D. H. Radia, J. Luebke, P. J. Bobbili, A. Wang, C. Norregaard, S. Dimitrijević, E. Sullivan, M. Louie-Gao, J. Schwaab, I. A. Galinsky, C. Perkins, W. R. Sperr, P. Sriskandarajah, A. Chin, S. R. Sendhil, M. S. Duh, P. Valent, D. J. DeAngelo

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


Search Tools: